Consistent with previous findings, 2 other meta-analyses revealed comparable efficacy and tolerability of ICIs between patients with NSCLC younger and older than 65 years of age: Sun et al analyzed data from 8 phase II/III studies that included 2662 patients <65 years and 1971 patients ≥65.19 The efficacy of anti-PD-1/PD-L1 agents was comparable between the 2 groups for OS but not for PFS. Here, CD274 is linked to non-small cell lung carcinoma.